RecruitMe Clinical Trial

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR-214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) OR ANTI-PD-L1 (ATEZOLIZUMAB) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
NKTR-214 in Combination with Pembrolizumab or Atezolizumab in Patients with Advanced or Metastatic Cancer (NSCLC, Bladder, or Melanoma)
Sponsor:Nektar Therapeutics
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9278
U.S. Government ID:NCT03138889
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18 years of age with a diagnosis of: Lung Cancer (Non-Small Cell Lung Cancer (NSCLC)), Bladder Cancer (Urothelial Carcinoma), or Skin Cancer (Melanoma). NKTR-214 has not been approved to treat cancer by the U.S. FDA or any other health or regulatory authority in other countries.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a diagnosis of Lung Cancer (NSCLC), Bladder Cancer (Urothelial Carcinoma), or Melanoma Cancer?YesNo
Are you willing to undergo additional biopsies while receiving study treatment?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162